Glenn Liu, MD Print Friendly PageFaculty, University of Wisconsin School of Medicine and Public Health
Dr. Liu joined the faculty as an Assistant Professor of Medicine at the University of Wisconsin in 2003, where he currently specializes in genitourinary oncology and experimental therapeutics. Previously, Dr. Liu did his undergraduate training at Dartmouth College, where he majored in biochemical engineering. From there, he received his Master's Degree at Boston University before obtaining his MD at Jefferson Medical College. Dr. Liu completed his internal medicine and oncology training at the University of Wisconsin Hospital and Clinics, with additional training in genitourinary oncology as part of a K12 grant at the University of Wisconsin Carbone Cancer Center.
UW Health Clinics
|Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.|
UW School of Medicine and Public Health
|Department of Medicine|
Professional Certifications and Education
UW Comprehensive Cancer Center
University of Wisconsin Hospital and Clinics, Madison, WI
University of Wisconsin Hospital and Clinics, Madison, WI
Jefferson Medical College, Philadelphia, PA, 1997
Our doctors provide a wide range of services. The following list represents some, but not all, of the procedures offered by this physician.
Dr. Liu specializes in the treatment of all genitourinary cancers and is a recognized clinical researcher as evident by his service on the Eastern Cooperative Oncology Group (ECOG) Genitourinary Oncology Core Committee as the Genitourinary (GU) Liaison for the ECOG Developmental Therapeutics Committee, for which he is also a member. He currently serves as the disease group leader for the GU Oncology Disease Group, a NCI-designated Phase II Consortium, and thus is highly active in local, regional, and national trials in all stages of development. Dr. Liu is also a member of the experimental therapeutics (Phase I) program at the UW Carbone Cancer Center, and thus is involved in early drug development.
McNeel DG Becker JT Eickhoff JC Johnson LE Bradley E Pohlkamp I Staab MJ Liu G Wilding G Olson BM .
Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer. Clin Cancer Res. 2014 Jul 15;20(14):3692-704
[PubMed ID: 24850844]
Simoncic U Perlman S Liu G Staab MJ Straus JE Jeraj R .
Comparison of NaF and FDG PET/CT for Assessment of Treatment Response in Castration-Resistant Prostate Cancers With Osseous Metastases. Clin Genitourin Cancer. 2014 Jul 15;
[PubMed ID: 25128349]
Wisinski KB Ledesma WM Kolesar J Wilding G Liu G Douglas J Traynor AM Albertini M Mulkerin D Bailey HH .
A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer. J Oncol Pharm Pract. 2014 Jul 1;
[PubMed ID: 24986793]
Schelman WR Mohammed TA Traynor AM Kolesar JM Marnocha RM Eickhoff J Keppen M Alberti DB Wilding G Takebe N Liu G .
A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer. Invest New Drugs. 2014 Apr;32(2):295-302
[PubMed ID: 23860642]
Bruce JY Kolesar JM Hammers H Stein MN Carmichael L Eickhoff J Johnston SA Binger KA Heideman JL Perlman SB Jeraj R Liu G .
A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies. Cancer Chemother Pharmacol. 2014 Mar;73(3):485-93
[PubMed ID: 24414551]
Lee KS De Smet AA Liu G Staab MJ .
High resolution ultrasound features of prostatic rib metastasis: a prospective feasibility study with implication in the high-risk prostate cancer patient. Urol Oncol. 2014 Jan;32(1):24.e7-11
[PubMed ID: 23481369]
Lang JM Wallace M Becker JT Eickhoff JC Buehring B Binkley N Staab MJ Wilding G Liu G Malkovsky M McNeel DG .
A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy. Clin Genitourin Cancer. 2013 Dec;11(4):407-15
[PubMed ID: 23835291]
Morisson C Jeraj R Liu G .
Imaging of castration-resistant prostrate cancer: development of imaging response biomarkers. Curr Opin Urol. 2013 May;23(3):230-6
[PubMed ID: 23422587]
Cetnar J Wilding G McNeel D LoConte NK McFarland TA Eickhoff J Liu G .
A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer. Urol Oncol. 2013 May;31(4):436-41
[PubMed ID: 21481618]
Liu G Chen YH Kolesar J Huang W Dipaola R Pins M Carducci M Stein M Bubley GJ Wilding G .
Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer. Urol Oncol. 2013 Feb;31(2):211-8
[PubMed ID: 21784672]
Bruce JY Lang JM McNeel DG Liu G .
Current controversies in the management of biochemical failure in prostate cancer. Clin Adv Hematol Oncol. 2012 Nov;10(11):716-22
[PubMed ID: 23271258]
McNeel DG Smith HA Eickhoff JC Lang JM Staab MJ Wilding G Liu G .
Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. Cancer Immunol Immunother. 2012 Jul;61(7):1137-47
[PubMed ID: 22210552]
Liu G Chen YH Dipaola R Carducci M Wilding G .
Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group. Clin Genitourin Cancer. 2012 Jun;10(2):99-105
[PubMed ID: 22386239]
Holen K DiPaola R Liu G Tan AR Wilding G Hsu K Agrawal N Chen C Xue L Rosenberg E Stein M .
A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors. Invest New Drugs. 2012 Jun;30(3):1088-95
[PubMed ID: 21424701]
Tevaarwerk A Wilding G Eickhoff J Chappell R Sidor C Arnott J Bailey H Schelman W Liu G .
Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design. Invest New Drugs. 2012 Jun;30(3):1039-45
[PubMed ID: 21225315]
Bruce JY Eickhoff J Pili R Logan T Carducci M Arnott J Treston A Wilding G Liu G .
A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate. Invest New Drugs. 2012 Apr;30(2):794-802
[PubMed ID: 21174224]
Hong H Severin GW Yang Y Engle JW Zhang Y Barnhart TE Liu G Leigh BR Nickles RJ Cai W .
Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105. Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):138-48
[PubMed ID: 21909753]
Liu G Jeraj R Vanderhoek M Perlman S Kolesar J Harrison M Simoncic U Eickhoff J Carmichael L Chao B Marnocha R Ivy P Wilding G .
Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate. Clin Cancer Res. 2011 Dec 15;17(24):7634-44
[PubMed ID: 22038997]
Harrison MR Hahn NM Pili R Oh WK Hammers H Sweeney C Kim K Perlman S Arnott J Sidor C Wilding G Liu G .
A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Invest New Drugs. 2011 Dec;29(6):1465-74
[PubMed ID: 20499131]
Yang Y Zhang Y Hong H Liu G Leigh BR Cai W .
In vivo near-infrared fluorescence imaging of CD105 expression during tumor angiogenesis. Eur J Nucl Med Mol Imaging. 2011 Nov;38(11):2066-76
[PubMed ID: 21814852]